Frontlight ResearchEarly access
WithdrawnPhase 2
Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Key facts
- Who runs it
- Shanghai Minimally Invasive Surgery Center
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 1 Nov 2023
- Ended
- 1 Oct 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Anlotinib+Capeox
- Capeox
- Record updated
- 28 September 2021
- Why it stopped
- No approval from ethical committee
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Subjects voluntarily join the study and sign an informed consent form, have good compliance and cooperate with follow-up
- Male or female patients between the ages of 18-75
- Patients diagnosed as rectal adenocarcinoma by histology or cytology
- Stage: Locally advanced stage (T3-4N0M0 or T1-4N+M0)
- Evaluation of middle and low rectal cancer with the lower pole of the tumor less than 12 cm from the anal margin by MRI
- Have not received other anti-angiogenic drugs or chemotherapy drugs in the past
- ECOG (Eastern US Cooperative Oncology Group) score: 0-1 points
- Has sufficient organ and bone marrow function
Who cannot take part
- Those who have multiple factors that affect oral medications (such as inability to swallow, chronic diarrhea, etc.)
- Received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before grouping
- Regardless of the severity, patients with any signs of bleeding or medical history; within 4 weeks before grouping, patients with any bleeding or bleeding events NCI-CTC AE V5.0 grade ≥ 3, unhealed wounds, ulcers Or fracture
- Participated in other anti-tumor drug clinical trials within four weeks
- According to the judgment of the investigator, those with concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study
- Other malignant tumors that have appeared or are currently suffering from within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) ) And T1 (tumor infiltration basement membrane)]
- Accompanied by pleural effusion or ascites, causing respiratory syndrome (NCI-CTC AE V5.0 grade ≥ 2 dyspnea)
- Patients with any severe and/or uncontrollable disease;
- Patients with gastrointestinal diseases with bleeding tendency (such as active gastrointestinal ulcers) or patients determined by the researcher to cause gastrointestinal bleeding, perforation or obstruction
- Patients whose imaging shows that the tumor has invaded the tissues around important blood vessels or the investigator judges that the tumor is likely to invade important blood vessels and cause fatal bleeding during the follow-up study
- Those who have had arterial/venous thrombotic events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism
- People with a history of psychotropic drug abuse and unable to quit or have mental disorders
- Known hypersensitivity to any study drug
- A distant transfer occurs
- Female patients who are pregnant or breastfeeding
About the trial
What the trial wants to find out
Prospectively Investigate the effectiveness and safety of anlotinib hydrochloride combined with Capeox in neoadjuvant treatment of patients with locally advanced rectal cancer.
The 2 groups in the trial
- Anlotinib+CapeoxTreatment being tested
neoadjuvant treatment with Anlotinib hydrochloride combined with Capeox
- CapeoxExisting treatment, for comparison
neoadjuvant treatment with Capeox
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal cancer-a Prospective, Open, Single Center and Randomized Controlled Phase Ⅱ Clinical Trial
- Record updated
- 28 September 2021